Drug Classification · Questions 1–6
Identify the pharmacological class or categorical label for each drug or receptor. Vocabulary preparation is sufficient to answer every question in this section.
Question 1
Ranolazine is classified as which type of antianginal agent?
Correct Answer
A) Late sodium current inhibitor
Rationale
Ranolazine is classified as a late sodium current inhibitor.
Question 2
Ivabradine is classified as which type of antianginal agent?
Correct Answer
B) Funny current inhibitor
Rationale
Ivabradine is classified as a funny current inhibitor, acting selectively within the sinoatrial node.
Question 3
Nicorandil is classified as which type of antianginal agent?
Correct Answer
C) Potassium channel opener with a nitrate-like component
Rationale
Nicorandil is classified as a potassium channel opener with a nitrate-like component, giving it a dual vasodilatory mechanism.
Question 4
Trimetazidine is classified as which type of antianginal agent?
Correct Answer
D) Metabolic modulator
Rationale
Trimetazidine is classified as a metabolic modulator, shifting cardiac metabolism toward glucose oxidation.
Question 5
Ranolazine is classified as available in which formulation type?
Correct Answer
A) Extended-release only
Rationale
Ranolazine is classified as available only in an extended-release formulation.
Question 6
Visual phosphenes are classified as the distinctive adverse effect of which drug?
Correct Answer
B) Ivabradine
Rationale
Visual phosphenes are classified as the most distinctive adverse effect of ivabradine.
Core Pharmacology · Questions 7–14
Apply your understanding of drug mechanisms, pharmacokinetics, and adverse effects. Each question requires one reasoning step.
Question 7
By which mechanism does blocking the abnormal late sodium current reduce myocardial ischemia?
Correct Answer
A) It interrupts the sodium-driven calcium overload that impairs diastolic relaxation and worsens ischemia
Rationale
During ischemia, an abnormal late sodium current allows excess sodium to build up inside the cell, which secondarily drives calcium overload. This impairs diastolic relaxation and worsens the ischemia that triggered the problem. Blocking the late sodium current interrupts this self-reinforcing cycle.
Question 8
Why does ranolazine not affect heart rate or blood pressure at therapeutic doses?
Correct Answer
C) Ranolazine's target, the late sodium current, is distinct from the ion channels that control heart rate and vascular tone
Rationale
Ranolazine selectively blocks the abnormal late sodium current that develops during ischemia, a target that is mechanistically distinct from the channels controlling heart rate and vascular smooth muscle tone, which is why it does not measurably affect heart rate, blood pressure, or contractility.
Question 9
Why does ivabradine slow heart rate without producing the contractility or atrioventricular conduction effects seen with beta-blockers or non-dihydropyridine calcium channel blockers?
Correct Answer
B) The funny current that ivabradine blocks is concentrated almost entirely in the sinoatrial node
Rationale
Ivabradine selectively blocks the funny current within the sinoatrial node. Because this current is concentrated almost entirely in the sinus node, ivabradine has no meaningful effect on contractility, blood pressure, or atrioventricular nodal conduction.
Question 10
Why does ivabradine have no rate-slowing effect in a patient with atrial fibrillation?
Correct Answer
D) In atrial fibrillation, the sinoatrial node is no longer driving the heart rhythm, so blocking its pacemaker current has no rate-slowing effect
Rationale
Because ivabradine acts specifically on the sinus node's pacemaker current, it has no rate-slowing effect when the sinus node is no longer driving the heart rhythm, as is the case in atrial fibrillation. Confirmed sinus rhythm is required before starting ivabradine.
Question 11
Why is a baseline electrocardiogram with corrected QT interval measurement required before starting ranolazine?
Correct Answer
A) Ranolazine produces weak blockade of a cardiac potassium channel, causing mild corrected QT interval prolongation
Rationale
Ranolazine produces mild prolongation of the corrected QT interval through weak blockade of a cardiac potassium channel. Baseline electrocardiogram and corrected QT interval measurement are required before starting, and ranolazine is contraindicated in patients with significant baseline corrected QT interval prolongation.
Question 12
Why does ivabradine cause visual phosphenes, transient bright flashes or halos of light?
Correct Answer
C) The same channel type that ivabradine blocks in the sinus node is also present in retinal tissue
Rationale
Visual phosphenes occur because the same type of channel ivabradine blocks in the sinus node is also present in the retina. These effects are reversible with dose reduction or discontinuation.
Question 13
Why does shifting cardiac metabolism from fatty acid oxidation toward glucose oxidation make each unit of oxygen delivered to the heart go further?
Correct Answer
B) Glucose oxidation consumes less oxygen per unit of energy produced than fatty acid oxidation
Rationale
The heart muscle normally relies heavily on fatty acid oxidation for energy, but this pathway consumes more oxygen per unit of energy produced than glucose oxidation does. Partially shifting cardiac metabolism toward glucose makes each unit of delivered oxygen go further, without any effect on heart rate, blood pressure, or contractility.
Question 14
Why is ranolazine particularly useful as an add-on agent in patients already on maximally tolerated beta-blocker, calcium channel blocker, and nitrate therapy?
Correct Answer
D) It has no hemodynamic effect, so it can be layered onto existing therapy without compounding dose-limiting bradycardia or hypotension
Rationale
Because every hemodynamic agent eventually runs into a dose-limiting side effect such as bradycardia or hypotension, ranolazine's lack of hemodynamic effect allows it to add anti-ischemic benefit without compounding these existing dose-limiting effects, which is why it is approved specifically as add-on therapy in patients who remain symptomatic despite adequate hemodynamic therapy.
Clinical Correlations · Questions 15–18
Apply pharmacological knowledge to clinical scenarios. Each vignette presents a patient situation; the question tests mechanism of action or drug selection.
Question 15
A 65-year-old man with stable angina remains symptomatic despite maximally tolerated doses of a beta-blocker, a calcium channel blocker, and a long-acting nitrate. He cannot tolerate further heart rate or blood pressure lowering. His physician adds ranolazine. Which of the following best explains why this addition does not further reduce his heart rate or blood pressure?
Correct Answer
C) Ranolazine selectively blocks the abnormal late sodium current, a mechanism distinct from the hemodynamic levers his other medications act on
Rationale
Ranolazine selectively blocks the abnormal late sodium current that develops during ischemia, improving diastolic relaxation and reducing oxygen consumption without measurably affecting heart rate, blood pressure, or contractility, making it suitable to add onto maximized hemodynamic therapy.
Question 16
A 70-year-old man with stable angina and an elevated resting heart rate is started on ivabradine after his electrocardiogram is misread as showing sinus rhythm. His heart rate does not improve. Repeat electrocardiogram review reveals he is actually in atrial fibrillation. Which of the following best explains why ivabradine had no effect on his heart rate?
Correct Answer
A) In atrial fibrillation, the sinoatrial node is no longer driving the heart rhythm, so blocking its pacemaker current has no rate-slowing effect
Rationale
Ivabradine acts specifically on the sinus node's pacemaker current. In atrial fibrillation, the sinus node is no longer driving the rhythm, so the drug has no rate-slowing effect. Rate control in atrial fibrillation requires drugs that act on the atrioventricular node instead, and confirmed sinus rhythm is required before starting ivabradine.
Question 17
A 58-year-old woman started on ivabradine three weeks ago for stable angina reports occasional brief flashes of light in her peripheral vision, particularly at night. Her ophthalmologic examination is otherwise unremarkable. Which of the following best explains this symptom?
Correct Answer
D) The same channel type ivabradine blocks in the sinus node is also present in retinal tissue
Rationale
Visual phosphenes are the most distinctive adverse effect of ivabradine, occurring because the same type of channel the drug blocks in the sinus node is also present in the retina. These effects are reversible with dose reduction or discontinuation.
Question 18
A 52-year-old woman with diabetes and stable angina is in sinus rhythm with a resting heart rate of 86 beats per minute despite a maximally tolerated dose of metoprolol. Her physician is choosing between adding ivabradine or ranolazine. Which agent is the more appropriate addition, and why?
Correct Answer
B) Ivabradine, because it directly addresses her persistently elevated heart rate, while ranolazine offers no heart rate benefit
Rationale
Ivabradine is used as add-on therapy in patients in sinus rhythm with an elevated resting heart rate despite maximally tolerated beta-blocker therapy, since it directly addresses the elevated rate. Ranolazine has no direct rate benefit, while a mild glucose-lowering benefit favors ranolazine specifically in patients with diabetes, which is a separate consideration not at issue in this scenario.